Intellia Therapeutics, Inc. (LON:0JBU)
10.54
+0.33 (3.23%)
At close: Aug 22, 2025
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $14.25M USD in the quarter ending June 30, 2025, with 104.76% growth. This brings the company's revenue in the last twelve months to $52.86M, up 14.99% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$52.86M
Revenue Growth
+14.99%
P/S Ratio
21.62
Revenue / Employee
$131.16K
Employees
403
Market Cap
834.14M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Oxford Nanopore Technologies | 183.19M |
Intellia Therapeutics News
- 17 days ago - Intellia Therapeutics Q2 2025 Earnings Preview - Seeking Alpha
- 22 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 23 days ago - Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - GlobeNewsWire
- 24 days ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 5 weeks ago - With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy' - Seeking Alpha
- 6 weeks ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus